Michael Claus V Jensen, MD

Michael Claus V Jensen, MD

High-Risk Leukemia Program

Children's Title: Vice President, Seattle Children's Therapeutics, and Chief Therapeutics Officer

Academic Title: Professor

  • Michael Jensen, MD, is a professor of hematology-oncology at the University of Washington School of Medicine. He is member of the clinical division in the Program in Immunology at Fred Hutchinson Cancer Center. Dr. Jensen holds the Janet and Jim Sinegal Endowed Chair in Pediatric Solid Tumor Research in Honor of Korey Rose.

    Dr. Michael Jensen graduated from the University of Pennsylvania School of Medicine then completed training in Pediatric Hematology and Oncology at the University of Washington/Fred Hutchinson Cancer Center. His laboratory work began under the mentorship of Dr. Philip Greenberg, Program Head in Immunology, Fred Hutch and focused on the immunobiology of tumor-specific T cells. Following completion of his fellowship, Dr. Jensen joined the faculty at the City of Hope National Medical Center, where he built a translational research program integrating gene therapy and cellular immunotherapy for cancer. This program grew into the Department of Cancer Immunotherapeutics & Tumor Immunology within the Beckman Research Institute and was incorporated into the institution's NCI-Comprehensive Cancer Center as the Cancer Immunotherapeutics Program with Dr. Jensen as its leader. During his tenure at City of Hope, Dr. Jensen's research program placed a strong emphasis on bench-to-bedside translational research and resulted in seven FDA-authorized Investigational New Drug Applications covering first-in-human applications of adoptive transfer of genetically engineered T cells having redirected tumor specificity for lymphoma, neuroblastoma and malignant gliomas. In 2010, Dr. Jensen joined the University of Washington School of Medicine faculty as a Professor of Pediatrics and is the founding director of the Ben Towne Center for Childhood Cancer Research. He holds the Janet and Jim Sinegal endowed chair in pediatric cancer research. Dr. Jensen is an adjunct professor of Bioengineering and Neurological Surgery at the University of Washington School of Medicine and a joint member of the Clinical Research Division at Fred Hutch. Dr. Jensen is an Associate Head of the Immunology and Vaccine Development Program of the UW-Fred Hutch Cancer Consortium and is a SU2C Dream Team Principal Investigator on the recently awarded Pediatric Cancer Research Immunogenomics Dream Team award.

    • Related Pages

    • Jensen Lab

      Jensen Lab

      At Seattle Children’s, the Jensen Lab is pursuing a cutting-edge treatment that reprograms a child’s defense system to attack and kill cancer cells, without chemotherapy or radiation – or their debilitating side effects.

    • Nathan Lynnwood, Washington 07.24.13

      Dr. Jensen was in his Fellowship at Seattle Children's in 1994-1995 and was instrumental in my battle with Non-Hogkins. It was a scary time, but his ability to explain the processes, side-affects, and outlook was confident and caring for my parents and myself. As a patient and a child, I wanted to know what was going on and why. Dr. Jensen took the time to converse candidly with me about the cancer, the treatments, and the schedule. I think these conversations helped me to not fear the cancer or the treatments, that the only thing to fear is what I do not know. Dr. Jensen and the team at Seattle Children's have a beautiful vision and I have hope and confidence they will make it happen. Contrary to what I was told were possibilities: The salt in the pepperoni sticks that were the only thing I wanted to eat during treatment, didn't hurt me. The sun might have been bad for the skin because of the treatments, but it was great for my spirit (my Dermatologist does agree that I should stay away from it though). The infertility rate of childhood cancer survivors went down about 6 years ago when my wife Kristy and I welcomed our son, Jonathan. We also have a daughter, Kaleah (16 months). I closed my account at "the bank" after finding out I didn't need what was deposited. I would encourage anyone who was treated for childhood cancer by any doctor or hospital to participate in a "Long Term Follow-Up" study. Doing so creates a wealth of knowledge and helps communicate the need for Doctor Jensen's research. These studies document the impact of childhood cancer and treatments on survivors and their quality of life. Thank You Dr. Jensen for your continued care in the battle, Nathan Schauermann Survivor, Non-Hogkins T-cell Lymphoma

    • Lacey Los Angeles, CA 12.02.11

      Dr. Jensen was my pediatric oncologist at a California hospital before he moved to Seattle Children's; and before I met him I was given a 30% chance to live. That was 12 years ago. To Dr. Jensen you are more than just a chart, number, or disease, you are a human being. His bedside manner, I have yet to see duplicated, and when he told me I was cancer free and would no longer need treatments, I cried, because I was going to miss HIM. I'm happy to say that I am doing well and I'm getting ready to celebrate my 25th birthday, a birthday I likely would not have had if not for Dr. Jensen. Thank you doctor for everything you have done for pediatric cancer patients everywhere, and for giving me my life back!

    Recommend Dr. Michael Claus V Jensen

  • Other Publications

    • Jensen MC, Riddell SR
      Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.
      24329794 Immunological reviews, 2014 Jan. : 257(1)127-44
    • Budde LE, Berger C, Lin Y, Wang J, Lin X, Frayo SE, Brouns SA, Spencer DM, Till BG, Jensen MC, Riddell SR, Press OW
      Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma.
      24358223 PloS one, 2013 Dec 17 : 8(12)e82742 PMCID:PMC3866194
    • Hunter MR, Prosser ME, Mahadev V, Wang X, Aguilar B, Brown CE, Forman SJ, Jensen MC
      Chimeric c cytokine receptors confer cytokine independent engraftment of human T lymphocytes.
      23628622 Molecular immunology, 2013 Nov. : 56(1-2)1-11
    • Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, Hoffman L, Aguilar B, Chang WC, Bretzlaff W, Chang B, Jonnalagadda M, Starr R, Ostberg JR, Jensen MC, Bhatia R, Forman SJ
      T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
      24030378 Blood, 2013 Oct 31 : 122(18)3138-48 PMCID:PMC3814731
    • Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, Riddell SR
      Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.
      23620405 Clinical cancer research : an official journal of the American Association for Cancer Research, 2013 Jun 15 : 19(12)3153-64 PMCID:PMC3804130
    • Jonnalagadda M, Brown CE, Chang WC, Ostberg JR, Forman SJ, Jensen MC
      Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy.
      23755242 PloS one, 2013 : 8(6)e65519 PMCID:PMC3675038
    • Riddell SR, Jensen MC, June CH
      Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyond.
      23085599 Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013 Jan. : 19(1 Suppl)S2-5 PMCID:PMC3654529
    • Wang X, Naranjo A, Brown CE, Bautista C, Wong CW, Chang WC, Aguilar B, Ostberg JR, Riddell SR, Forman SJ, Jensen MC
      Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.
      23090078 Journal of immunotherapy (Hagerstown, Md. : 1997), 2012 Nov. : 35(9)689-701 PMCID:PMC3525345
    • Turtle CJ, Hudecek M, Jensen MC, Riddell SR
      Engineered T cells for anti-cancer therapy.
      22818942 Current opinion in immunology, 2012 Oct. : 24(5)633-9 PMCID:PMC3622551
    • Prosser ME, Brown CE, Shami AF, Forman SJ, Jensen MC
      Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.
      22503210 Molecular immunology, 2012 July : 51(3-4)263-72
    • Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE, Raubitschek A, Forman SJ, Greenberg PD, Riddell SR, Press OW
      CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
      22308288 Blood, 2012 Apr 26 : 119(17)3940-50 PMCID:PMC3350361
    • Brown CE, Starr R, Aguilar B, Shami AF, Martinez C, D'Apuzzo M, Barish ME, Forman SJ, Jensen MC
      Stem-like tumor-initiating cells isolated from IL13R2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.
      22407828 Clinical cancer research : an official journal of the American Association for Cancer Research, 2012 Apr 15 : 18(8)2199-209 PMCID:PMC3578382
    • Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell SR
      Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.
      22031866 Blood, 2012 Jan 5 : 119(1)72-82 PMCID:PMC3251238
    • Zou Z, Denny E, Brown CE, Jensen MC, Li G, Fujii T, Neman J, Jandial R, Chen M
      Cytotoxic T lymphocyte trafficking and survival in an augmented fibrin matrix carrier.
      22496835 PloS one, 2012 : 7(4)e34652 PMCID:PMC3319597
    • Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR, Forman SJ, Riddell SR, Jensen MC
      A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.
      21653320 Blood, 2011 Aug 4 : 118(5)1255-63 PMCID:PMC3152493
    • Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, Jensen MC
      Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice.
      21123821 Blood, 2011 Feb 10 : 117(6)1888-98 PMCID:PMC3056638
    • Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR
      The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.
      20702778 Blood, 2010 Nov 25 : 116(22)4532-41 PMCID:PMC2996114
    • Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, Forman SJ
      Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.
      20304086 Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010 Sept. : 16(9)1245-56 PMCID:PMC3383803
    • Alizadeh D, Zhang L, Brown CE, Farrukh O, Jensen MC, Badie B
      Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.
      20570924 Clinical cancer research : an official journal of the American Association for Cancer Research, 2010 Jul 1 : 16(13)3399-408 PMCID:PMC3022005
    • Cao LF, Krymskaya L, Tran V, Mi S, Jensen MC, Blanchard S, Kalos M
      Development and application of a multiplexable flow cytometry-based assay to quantify cell-mediated cytolysis.
      20229499 Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2010 June : 77(6)534-45
    • Chen YY, Jensen MC, Smolke CD
      Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems.
      20421500 Proceedings of the National Academy of Sciences of the United States of America, 2010 May 11 : 107(19)8531-6 PMCID:PMC2889348
    • James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Budde LE, Till BG, Raubitschek AA, Forman SJ, Press OW
      Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation.
      20220093 Journal of immunology (Baltimore, Md. : 1950), 2010 Apr 15 : 184(8)4284-94 PMCID:PMC2896691
    • James SE, Orgun NN, Tedder TF, Shlomchik MJ, Jensen MC, Lin Y, Greenberg PD, Press OW
      Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.
      19880489 Blood, 2009 Dec 24 : 114(27)5454-63 PMCID:PMC2798862
    • Brown CE, Starr R, Martinez C, Aguilar B, D'Apuzzo M, Todorov I, Shih CC, Badie B, Hudecek M, Riddell SR, Jensen MC
      Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells.
      19903840 Cancer research, 2009 Dec 1 : 69(23)8886-93 PMCID:PMC2789196
    • Berger C, Berger M, Hackman RC, Gough M, Elliott C, Jensen MC, Riddell SR
      Safety and immunologic effects of IL-15 administration in nonhuman primates.
      19605850 Blood, 2009 Sep 17 : 114(12)2417-26 PMCID:PMC2746471
    • Berger C, Turtle CJ, Jensen MC, Riddell SR
      Adoptive transfer of virus-specific and tumor-specific T cell immunity.
      19304470 Current opinion in immunology, 2009 April : 21(2)224-32 PMCID:PMC2720155
    • Yaghoubi SS, Jensen MC, Satyamurthy N, Budhiraja S, Paik D, Czernin J, Gambhir SS
      Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma.
      19015650 Nature clinical practice. Oncology, 2009 Jan. : 6(1)53-8 PMCID:PMC3526373
    • Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ, Gopal AK, Pagel JM, Lindgren CG, Greenberg PD, Riddell SR, Press OW
      Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
      18509084 Blood, 2008 Sep 15 : 112(6)2261-71 PMCID:PMC2532803
    • Lazovic J, Jensen MC, Ferkassian E, Aguilar B, Raubitschek A, Jacobs RE
      Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme.
      18559603 Clinical cancer research : an official journal of the American Association for Cancer Research, 2008 Jun 15 : 14(12)3832-9 PMCID:PMC2737486
    • James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, Raubitschek AA, Forman SJ, Press OW
      Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.
      18453625 Journal of immunology (Baltimore, Md. : 1950), 2008 May 15 : 180(10)7028-38 PMCID:PMC2585549
    • Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR
      Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.
      18060041 The Journal of clinical investigation, 2008 Jan. : 118(1)294-305 PMCID:PMC2104476
    • Jensen MC
      Engineering GVL through T cell gene transfer.
      18162214 Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008 Jan. : 14(1 Suppl 1)5
    • Stastny MJ, Brown CE, Ruel C, Jensen MC
      Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells.
      17921847 Journal of pediatric hematology/oncology, 2007 Oct. : 29(10)669-77
    • Tran CA, Burton L, Russom D, Wagner JR, Jensen MC, Forman SJ, DiGiusto DL
      Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacity.
      17667528 Journal of immunotherapy (Hagerstown, Md. : 1997), 2007 Sept. : 30(6)644-54
    • Brown CE, Vishwanath RP, Aguilar B, Starr R, Najbauer J, Aboody KS, Jensen MC
      Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells.
      17709550 Journal of immunology (Baltimore, Md. : 1950), 2007 Sep 1 : 179(5)3332-41
    • Numbenjapon T, Serrano LM, Chang WC, Forman SJ, Jensen MC, Cooper LJ
      Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells.
      17588477 Experimental hematology, 2007 July : 35(7)1083-90
    • Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, Meechoovet HB, Bautista C, Chang WC, Ostberg JR, Jensen MC
      Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.
      17299405 Molecular therapy : the journal of the American Society of Gene Therapy, 2007 April : 15(4)825-33
    • Singh H, Serrano LM, Pfeiffer T, Olivares S, McNamara G, Smith DD, Al-Kadhimi Z, Forman SJ, Gillies SD, Jensen MC, Colcher D, Raubitschek A, Cooper LJ
      Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.
      17363611 Cancer research, 2007 Mar 15 : 67(6)2872-80
    • Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO
      Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.
      17159987 Nature medicine, 2007 Jan. : 13(1)84-8
    • Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJ
      CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
      17108138 Cancer research, 2006 Nov 15 : 66(22)10995-1004
    • Serrano LM, Pfeiffer T, Olivares S, Numbenjapon T, Bennitt J, Kim D, Smith D, McNamara G, Al-Kadhimi Z, Rosenthal J, Forman SJ, Jensen MC, Cooper LJ
      Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.
      16352804 Blood, 2006 Apr 1 : 107(7)2643-52 PMCID:PMC1895371
    • Otto-Duessel M, Khankaldyyan V, Gonzalez-Gomez I, Jensen MC, Laug WE, Rosol M
      In vivo testing of Renilla luciferase substrate analogs in an orthotopic murine model of human glioblastoma.
      16954019 Molecular imaging, 2006 April : 5(2)57-64
    • Vishwanath RP, Brown CE, Wagner JR, Meechoovet HB, Naranjo A, Wright CL, Olivares S, Qian D, Cooper LJ, Jensen MC
      A quantitative high-throughput chemotaxis assay using bioluminescent reporter cells.
      15987642 Journal of immunological methods, 2005 July : 302(1-2)78-89
    • Gonzalez S, Castanotto D, Li H, Olivares S, Jensen MC, Forman SJ, Rossi JJ, Cooper LJ
      Amplification of RNAi--targeting HLA mRNAs.
      15851019 Molecular therapy : the journal of the American Society of Gene Therapy, 2005 May : 11(5)811-8
    • Cooper LJ, Al-Kadhimi Z, Serrano LM, Pfeiffer T, Olivares S, Castro A, Chang WC, Gonzalez S, Smith D, Forman SJ, Jensen MC
      Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.
      15507526 Blood, 2005 Feb 15 : 105(4)1622-31
    • Brown CE, Wright CL, Naranjo A, Vishwanath RP, Chang WC, Olivares S, Wagner JR, Bruins L, Raubitschek A, Cooper LJ, Jensen MC
      Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing.
      15777929 Journal of immunological methods, 2005 Feb. : 297(1-2)39-52
    • Cooper LJ, Kalos M, DiGiusto D, Brown C, Forman SJ, Raubitschek A, Jensen MC
      T-cell genetic modification for re-directed tumor recognition.
      16110618 Cancer chemotherapy and biological response modifiers, 2005 : 22293-324
    • Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC
      Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
      15604287 Cancer research, 2004 Dec 15 : 64(24)9160-6
    • Cooper LJ, Al-Kadhimi Z, DiGiusto D, Kalos M, Colcher D, Raubitschek A, Forman SJ, Jensen MC
      Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies.
      15223016 Blood cells, molecules & diseases, 2004 July : 33(1)83-9
    • Cooper LJ, Topp MS, Pinzon C, Plavec I, Jensen MC, Riddell SR, Greenberg PD
      Enhanced transgene expression in quiescent and activated human CD8+ T cells.
      15242525 Human gene therapy, 2004 July : 15(7)648-58
    • Gonzalez S, Naranjo A, Serrano LM, Chang WC, Wright CL, Jensen MC
      Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma.
      15170741 The journal of gene medicine, 2004 June : 6(6)704-11
    • Wang J, Press OW, Lindgren CG, Greenberg P, Riddell S, Qian X, Laugen C, Raubitschek A, Forman SJ, Jensen MC
      Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.
      15093188 Molecular therapy : the journal of the American Society of Gene Therapy, 2004 April : 9(4)577-86
    • Topp MS, Riddell SR, Akatsuka Y, Jensen MC, Blattman JN, Greenberg PD
      Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production.
      12963692 The Journal of experimental medicine, 2003 Sep 15 : 198(6)947-55 PMCID:PMC2194206
    • Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A, Wright C, Popplewell L, Raubitschek A, Forman SJ, Jensen MC
      T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.
      12393484 Blood, 2003 Feb 15 : 101(4)1637-44

    Show More Hide